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Background: There are limited number of studies investigating extrapulmonary manifestations of bronchiectasis.
The purpose of this study was to compare peripheral muscle function, exercise capacity, fatigue, and health status
between patients with bronchiectasis and healthy subjects in order to provide documented differences in these
characteristics for individuals with and without bronchiectasis.
Methods: Twenty patients with bronchiectasis (43.5 ± 14.1 years) and 20 healthy subjects (43.0 ± 10.9 years)
participated in the study. Pulmonary function, respiratory muscle strength (maximal expiratory pressure – MIP - and
maximal expiratory pressure - MEP), and dyspnea perception using the Modified Medical Research Council Dyspnea
Scale (MMRC) were determined. A six-minute walk test (6MWT) was performed. Quadriceps muscle, shoulder
abductor, and hand grip strength (QMS, SAS, and HGS, respectively) using a hand held dynamometer and
peripheral muscle endurance by a squat test were measured. Fatigue perception and health status were
determined using the Fatigue Severity Scale (FSS) and the Leicester Cough Questionnaire (LCQ), respectively.
Results: Number of squats, 6MWT distance, and LCQ scores as well as lung function testing values and respiratory
muscle strength were significantly lower and MMRC and FSS scores were significantly higher in patients with
bronchiectasis than those of healthy subjects (p< 0.05). In bronchiectasis patients, QMS was significantly associated
with HGS, MIP and MEP (p< 0.05). The 6MWT distance was significantly correlated to LCQ psychological score
(p< 0.05). The FSS score was significantly associated with LCQ physical and total and MMRC scores (p< 0.05). The
LCQ psychological score was significantly associated with MEP and 6MWT distance (p< 0.05).
Conclusions: Peripheral muscle endurance, exercise capacity, fatigue and health status were adversely affected by
the presence of bronchiectasis. Fatigue was associated with dyspnea and health status. Respiratory muscle strength
was related to peripheral muscle strength and health status, but not to fatigue, peripheral muscle endurance or
exercise capacity. These findings may provide insight for outcome measures for pulmonary rehabilitation programs
for patients with bronchiectasis.
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Bronchiectasis is a chronic pulmonary disease which is
caused by the destruction of elastic tissue and smooth
muscles on bronchial walls due to repeated severe infection
or inflammation and characterized by abnormal permanent
dilatation [1]. Previous studies determined that skeletal
muscle (respiratory and limb) abnormalities in addition to
respiratory tract involvement are present in chronic inflam-
matory pulmonary diseases [2]. In these diseases, muscle
dysfunction is caused by inflammation, gas exchange ab-
normalities, electrolyte imbalance, inactivity, malnutrition
and drugs [2]. Peripheral muscle weakness and lack of en-
durance negatively affect the exercise capacity and percep-
tion of fatigue in chronic respiratory airway diseases [2-4].
Bronchiectasis is a common health problem for adult
populations in developing countries [5]; however there is a
limited number of studies investigating exercise capacity
in adult patients [6-9]. Peripheral muscle function has not
been studied in adult patients with bronchiectais. No study
was found by the authors in the literature that provided
findings in comparison with the results of healthy indivi-
duals. In the limited number of studies found, physical di-
mension of quality of life and localization of the disease
were reported to affect exercise capacity [8], depression
was related to exercise performance [7], and perception
of dyspnea was related to exercise capacity [6]. No study
associating peripheral and respiratory muscle weakness
in bronchiectasis with exercise capacity, respiratory
function and health status was found in the literature.
Therefore, the aim of the present study was to evaluate
extrapulmonary manifestations of bronchiectasis namely
peripheral muscle function, exercise capacity, fatigue
and health status of adult patients with bronchiectasis in
comparison with healthy individuals to provide data
about deviation from the normal values of these charac-
teristics in individuals with bronchiectasis.
Methods
The study included 20 adult patients with bronchiectasis
diagnosed in the Department of Chest Medicine by high
resolution computed tomography (10 F, 10 M) and 20
healthy subjects (13 M, 7 F). Consecutive patients who
were referred to the Cardiopulmonary Rehabilitation
Unit participated in the study. The mean (± SD) number
of lobes showing changes of bronchiectasis was 2.9 ± 1.0
(median: 3, range 1–5 lobes). The mean (± SD) time
from the diagnosis was 12.8 ± 11.8 years (median: 8,
range 1–33 years). Individuals who were using antibio-
tics, had neurologic or orthopedic disease, advanced
heart failure, or an acute exacerbation within the last
three weeks were not included in the study. The control
group was composed of individuals who had no known
systemic, orthopedic or neurologic disease, aged be-
tween 18–64 years, could walk and cooperate, and werevoluntary subjects among the relatives of researchers and
academic personnel. Participants were informed about the
aim and scope of the study, and written consent was
obtained from each participant. This prospective study was
approved by Ethical Committee of Hacettepe University.
Physical, physiological and socio-demographic character-
istics of the subjects were recorded. Body Mass Index
(BMI) was calculated by the formula of weight/height2
(kg/m2). Fat free mass (FFM) was determined using the
skinfold method (Skinfold Caliper, Holtain Ltd, Crosswell,
UK) from biceps, triceps, subscapular, and suprailiac
regions. Measurements were repeated three times and the
mean of three measurements was used [10].
The pulmonary function test was performed in sitting
position using a spirometer (Spirolab III Medical Inter-
national Research, Rome, Italy). Forced vital capacity
(FVC), forced expiratory volume in one second (FEV1),
FEV1/FVC, peak expiratory flow (PEF) and forced expira-
tory flow 25–75% (FEF25–75%) values were recorded. Para-
meters of the respiratory function test were expressed as
percentages of the expected values in accordance with the
subject’s age, height, body weight and sex [11].
Respiratory muscle strength was measured with a
portable electronic mouth pressure device (Micro Medical
MicroMPM, UK). Maximal inspiratory and expiratory
mouth pressures (MIP and MEP) were recorded. MIP was
measured at residual volume, while MEP was determined
at total lung capacity. Measurements were repeated three
times to avoid any difference larger than 10% or 10 cm
H2O and the best measurement analysis was chosen.
Values were expressed as percentages of the expected
values in terms of age and sex [12].
Perception of dyspnea was evaluated by the Modified
Medical Research Council (MMRC) dyspnea scale. The
MMRC is a 0–4 point category scale which selects the
best expression to define the dyspnea levels among five
expressions related to dyspnea [13].
Peripheral muscle strength of the participants (quadri-
ceps, shoulder abductor and hand grip strength) was
evaluated by digital dynamometer (JTECH, Medical
Commander Powertrack II, USA). Measurements were
repeated three times for the dominant side [14]. The
highest value of the measurements was expressed in
Newton (N). Peripheral muscle endurance was assessed
by a squat test. In the squat test, subjects were asked to
move from a standing position to a squatting position.
The number of squats completed in thirty seconds was
recorded for analysis [14].
For the six-minute walk test (6MWT), subjects were
asked to walk along a flat corridor at their walking speed as
quickly as possible for six minutes [15]. In pre- and post-
test periods, values of oxygen saturation were measured by
pulse oximeter (KPTS-01, Seoul, Korea). Heart rate, blood
pressure and respiratory rate were also recorded. Perception







Age (years) 43.5 ± 14.1 43.0 ± 10.9 0.891
Sex (male/female) 10/10 13/7 0.52
Height (cm) 165.6 ± 8.7 164.7 ± 7.6 0.72
Body weight (kg) 68.8 ± 16.4 75.4 ± 12.9 0.17
Body mass index
(kg/m2)
24.8 ± 4.6 27.96 ± 5.2 0.06
FFM (kg) 50.4 ± 11.4 56.23 ± 10.4 0.096
FVC (%) 70.4 ± 15.9 100.3 ± 12.7 < 0.0001*
FEV1 (%) 62.5 ± 20.0 97.3 ± 10.7 < 0.0001*
FEV1/FVC (%) 73.4 ± 14.8 80.9 ± 5.4 0.045*
PEF (%) 63.9 ± 23.3 101.8 ± 15.2 < 0.0001*
FEF25–75% (%) 45.4 ± 24.0 80.2 ± 17.2 < 0.0001*
MIP (cmH2O) 97.5 ± 30.3 115.8 ± 19.9 0.030*
%MIP 99.0 ± 28.1 109.4 ± 21.4 0.019*
MEP (cmH2O) 125.8 ± 33.6 170.0 ± 47.0 0.003*
%MEP 68.0 ± 13.8 85.7 ± 23.2 0.006*
MMRC (0–4) 1.55 ± 0.60 0.20 ± 0.52 < 0.0001*
*p< 0.05.
Table 1 legend - FEF25-75%, forced expiratory flow 25–75%; FEV1, forced
expiratory volume in one second; FFM, fat free mass; FVC, forced vital capacity;
MIP, maximal inspiratory pressure; MEP, maximal expiratory pressure; MMRC,
Modified Medical Research Council dyspnea scale, PEF, peak expiratory flow
rate.
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assessed with the Modified Borg Scale, which is a 0–10
point category scale [16]. Upon completion of the test, the
distance covered in the 6-minute walk was recorded in
meters. The 6MWT was applied twice with an interval of
half an hour on the same day. For each patient, the longer
walking distance of two tests was used for statistical analysis
[16]. The 6MWT distances expressed as percentages of
expected values from age and sex (6MWT% of distance)
were calculated [17].
The Fatigue Severity Scale (FSS) was used to estimate
the fatigue level of the subjects [18]. The FSS is a one-
dimensional scale developed to assess fatigue and com-
posed of nine items. The subject is asked to score each
expression between 1 (completely agree) and 7 (completely
disagree). In the FSS, ≥ 4 points implies the presence of
severe fatigue [18].
Health status was assessed using the Leicester Cough
Questionnaire (LCQ). The LCQ is composed of 19 items
and includes physical (8 items), psychological (7 items)
and social (4 items) sub-dimensions. Each item is scored
between 1 (always) and 7 (never). The score of each sub-
dimension ranges between 1 and 7. Total score ranges
between 3 and 21. Low scores on the LCQ indicate a
higher effect of coughing on the subject [19].
SPSS 15.0 packet software was used for the statistical
analysis [20]. Variables were expressed as mean± standard
deviation, frequency and percentages. The Shapiro Wilk
test was used to analyze the suitability of variables to nor-
mal distribution [21]. The Student’s t-test was used for the
comparison of variables suitable for normal distribution.
Mann–Whitney u-test was used to compare nonpara-
metric variables not suitable for normal distribution. Com-
parison of the variables determined by counting was
performed by the Chi-Square test. Corrected correlations
(for age, weight, height and sex) were used to investigate
association among the variables. The level of significance
was set to p< 0.05.
Results
Physical and demographic characteristics of patients with
bronchiectasis and healthy subjects were similar in the
study (p> 0.05, Table 1). FVC, FEV1, FEV1/FVC, PEF,
FEF25-75%, MIP, and MEP were significantly lower in
patients with bronchiectasis compared to healthy sub-
jects (p< 0.05, Table 1). The MIP of four subjects (20%)
and MEP value of 15 subjects (75%) were lower than
80% of their predicted value. The perception of dyspnea
in subjects with bronchiectasis determined using the
MMRC was significantly higher than that in healthy sub-
jects (p< 0.05, Table 1).
Although no significant difference was found between
subjects with bronchiectasis and healthy subjects regarding
peripheral muscle strength measures (p> 0.05, Table 2),quadriceps muscle strength tended to be lower in the group
with bronchiectasis (p=0.050, Table 2). Quadriceps muscle
strength was significantly associated with hand grip
strength (r = 0.52, p=0.037), MIP (r = 0.58, p=0.020) and
MEP (r =0.66, p=0.029) in patients with bronchiectasis.
The SAS was significantly correlated with MEP (r= 0.53,
p=0.035), and HGS was significantly associated with MIP
(r =0.52, p=0.040).
The number of squats was significantly lower in sub-
jects with bronchiectasis compared to healthy subjects
(p< 0.05, Table 2). It was not significantly related with
any of the variables measured (p> 0.05).
The 6MWT distance and 6MWT% distance were sig-
nificantly lower in subjects with bronchiectasis when
compared to the healthy group, while exercise dyspnea
perception was significantly higher in subjects with bron-
chiectasis (p< 0.05, Table 2). No significant difference
was noted between the two groups in maximal heart rate
percentage, oxygen saturation, blood pressure, general fa-
tigue or quadriceps fatigue perceptions recorded during
the test (p> 0.05). The 6MWT distance was significantly
related to LCQ psychological score (r = 0.52, p=0.042) in
patients with bronchiectasis.
Thirteen patients (65%) with bronchiectasis reported
having severe fatigue. The FSS value was significantly
higher in the bronchiectasis compared to the healthy
group (p< 0.05, Table 2). It was significantly associated
Table 2 Peripheral muscle function, exercise capacity,








Knee extension (N) 266.7 ± 63.3 310.4 ± 73.0 0.050
Shoulder abduction (N) 158.6 ± 56.7 183.0 ± 50.6 0.15
Hand grip (N) 176.9 ± 62.0 198.7 ± 54.5 0.18
Peripheral muscle endurance
Squats (n) 15.80 ± 3.28 22.50 ± 4.43 < 0.0001*
Fatigue
Fatigue Severity Scale 4.66 ± 1.67 3.37 ± 1.53 0.007*
Exercise capacity
6MWT distance (m) 559.2 ± 98.7 636.0 ± 74.3 0.008*
6MWT% 90.5 ± 14.3 105.6 ± 12.5 0.001*
Borg-dyspnea 2.20 ± 1.90 0.07 ± 0.24 < 0.001*
Borg-fatigue 1.77 ± 1.89 0.92 ± 1.43 0.26
Borg-quadriceps fatigue 1.65 ± 1.89 0.95 ± 2.30 0.16
Health status
LCQ total 14.67 ± 3.88 19.43 ± 1.33 < 0.0001*
LCQ physical 4.51 ± 1.37 6.53 ± 0.75 < 0.0001*
LCQ psychological 4.81 ± 1.12 6.01 ± 0.32 < 0.0001*
LCQ social 5.33 ± 1.65 6.87 ± 0.32 < 0.0001*
*p< 0.05.
Table 2 legend - 6MWT, six minute walk test; LCQ, Leicester Cough
Questionnaire.
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score (r =−0.50, p= 0.047) and MMRC score (r = 0.53,
p= 0.043).
The LCQ total score and the scores of physical, psy-
chological and social sub-dimensions were significantly
lower in the bronchiectasis group than in healthy subjects
(p< 0.0001, Table 2). The LCQ total score was signifi-
cantly related to FSS (r=−0.50, p=0.047), and physical
score was significantly and inversely related to FSS
(r =−0.56, p=0.024). The LCQ psychological score was
significantly associated with MEP (r = 0.51, p=0.044) and
6MWT distance (r = 0.52, p=0.042).Discussion
The present study demonstrated that bronchiectasis
affects peripheral muscle endurance, exercise capacity,
fatigue, and health status in addition to its effects on pul-
monary function, inspiratory and expiratory muscle
strength, and dyspnea perception in adult subjects with
bronchiectasis. Exercise capacity is related to health status.
Fatigue is affected by dyspnea perception and health
status.
Different levels of respiratory dysfunction could be seen
in bronchiectasis [5,22]. Mucociliary clearance dysfunction,
bronchial inflammation and infection, irreversible bronchialdilatation, and destruction in elastic and muscular compo-
nents of bronchial walls decreased expiratory air flow in
the lungs [1,5,23]. Effects on pulmonary function could be
seen as obstructive, restrictive or of a mixed type [5,22].
According to the results of pulmonary function tests in the
study, mild airflow obstruction was determined in large air-
ways, while severe obstruction was present in medium or
small airways. These findings indicate that pulmonary func-
tion in our patients with bronchiectasis showed a pattern
of airflow limitation probably due to chronic inflammation
and destroyed bronchial wall [5,22-24].
In the present study, MIP and MEP were decreased in
bronchiectasis. The MIP was lower than 80% of the
expected value in four subjects, and MEP was lower in
15 subjects. This finding is considered significant as it
demonstrates the presence of respiratory muscle weak-
ness which is especially evident for expiratory muscles in
subjects with bronchiectasis. Respiratory muscle strength
has been measured for adult patients with bronchiectasis
in a limited number of studies in literature [9,25,26]. In
the present study, the obtained MIP and MEP values
were higher than the measurements reported by Moran
et al. (MIP: 74.20 cmH2O; MEP: 104.30 cmH2O), Newall
et al. (MIP: 73.86 cmH2O; MEP: 86.83 cmH2O), and
Murray et al. (MIP: 43.5 cmH2O; MEP: 68.5 cmH2O)
[9,25,26] probably due to the inclusion of younger
patients with bronchiectasis who had better respiratory
function.
Dyspnea is seen in 60% of patients with bronchiectasis
[5,24]. We used MMRC to evaluate dyspnea, which is
considered one of the major factors defining bronchiec-
tasis [27] and affects the survival along with airway ob-
struction, pulmonary hyperinflation and frequency of
disease [1]. In the present study, dyspnea perception was
evidently higher in patients with bronchiectasis when
compared to the healthy group, which demonstrates that
MMRC could distinguish the dyspnea level between sub-
jects with bronchiectasis and healthy groups.
In a comprehensive evaluation of skeletal muscle func-
tion, peripheral muscle strength and peripheral muscle
endurance must be considered together [3]. In this re-
gard, the present study is the first in the literature to in-
vestigate peripheral muscle strength and endurance in
adult patients with bronchiectasis. In our study, isotonic
muscle strength of quadriceps tended to be lower than
the values of the healthy group, while the peripheral
muscle endurance was evidently reduced. Quadriceps
muscle strength was found to be related to inspiratory
and expiratory muscle strength and peripheral muscle
endurance in patients with bronchiectasis. Peripheral
muscle endurance was associated with expiratory muscle
strength, upper and lower extremity muscle strength, ex-
ercise capacity, and fatigue perception. However, MEP
was the only variable having an independent relationship
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was the only variable having an independent association
with peripheral muscle endurance. Skeletal muscles play an
important role both in motor (ventilation, ambulation and
postural control) and non motor functions (thermoregula-
tion and systemic metabolism) [28]. These neural networks
and the vulnerability of skeletal muscles - respiratory or
peripheral - to systemic disorders [28] including chronic
lung diseases may be responsible for the above mentioned
associations we found in terms of muscle dysfunction in
our bronchiectatic patients. Further study is needed to
clarify the cause of this deteriorating peripheral muscle
function.
In previous studies investigating exercise capacity of
adult patients with bronchiectasis, exercise performance
was reported to be reduced [6-9]. In the present study,
exercise capacity was examined using 6MWT and it was
found to be lower when compared to healthy subjects.
The 6MWT distance was significantly related to expiratory
muscle strength, peripheral muscle strength and endurance.
Hand grip strength was the only variable having an inde-
pendent association with 6MWT distance. Peripheral
muscle strength is a strong determinant of 6MWT in
chronic lung disease [29], and hand grip strength is thought
to be representative of general strength [30]. The lower
exercise capacity of subjects with bronchiectasis could
be caused by increased mucus production, deterioration
in respiratory function, decrease in respiratory muscle
strength, impaired health related quality of life [8], and
loss of peripheral muscle endurance.
In recent years, fatigue has been reported to be com-
monly present in chronic pulmonary disease. At clinical
investigation, it was determined to be present in as many
as 74% of patients [5,31]. In a study evaluating fatigue
perception of subjects with bronchiectasis using a stan-
dardized questionnaire, fatigue sense was determined to
be higher in patients with bronchiectasis who had higher
anxiety and depression levels [7]. In the present study,
severity of fatigue as estimated by the FSS (a standar-
dized measurement method) was found to be increased
in subjects with bronchiectasis compared to a healthy
group, and it was concluded as being severe (FSS ≥ 4
points) in the majority of the patients. These findings
prove that fatigue is an important symptom for patients
with bronchiectasis similarly to patients with COPD. In
our patients with bronchiectasis fatigue was associated with
dyspnea and health status. This finding suggests that fa-
tigue should be evaluated using standardized specific ques-
tionnaires since it may not be predicted from the clinical
measures including both pulmonary and peripheral
variables.
In the limited number of studies examining health status
of patients with bronchiectasis, impaired health status was
found using a disease-specific standard questionnaire[8,25,32-36]. Dyspnea perception, FEV1 and daily amount
of produced mucus are the factors independently affecting
health status in patients with bronchiectasis [33]. In the
present study, the effect of coughing symptoms frequently
observed in bronchiectasis on health status was examined
using LCQ. The difference with respect to healthy subjects
was concluded to be higher than 1.3 points, which is a
clinically significant level [37]. According to these results,
the health status of subjects with bronchiectasis is evi-
dently affected by the disease. In our study, an impaired
physical component of disease-specific health status was
associated with increased fatigue and dyspnea perception.
In general, impaired health status was influenced only by
fatigue perception. These findings reveal that frequent
subjective symptoms have an effect on health status in
clinically stable adult patients with bronchiectasis.
In this study, we used healthy controls for the com-
parison of extrapulmonary features of muscle function,
exercise capacity, fatigue, and health status in patients
with bronchiectasis. Although skeletal muscles involve-
ment is frequent in COPD patients, we did not use a
control group consisting of COPD patients with the
same obstruction but preferred to use healthy subjects,
since investigations that lack a healthy control group are
not able to provide documented differences in the extra-
pulmonary characteristics between individuals with vs.
without bronchiectasis. In our study, healthy subjects pro-
vided data concerning deviation from the normal values. A
search of similar articles in the literature revealed that they
did not include any controls [5-8,31-35]. Since the aim of
the study was not to compare two different obstructive
diseases, we wanted to provide findings showing how
bronchiectasis patients’ extrapulmonary status was
affected by their respiratory status.
Conclusions
In conclusion, we found that perceptions of dyspnea and
fatigue, peripheral muscle endurance, exercise capacity
and health status are affected by the disease in subjects
with bronchiectasis in addition to pulmonary function,
inspiratory and expiratory respiration muscle strength.
These extrapulmonary features of bronchiectasis may
provide insight for outcome measures for pulmonary re-
habilitation programs in patients with bronchiectasis.
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